Indian pharma stocks witnessed sharp selling pressure as US President Donald Trump unveiled a phased tariff plan on imported generic medicines. The Nifty Pharma index slipped nearly 2%, with every constituent trading in the red within the first 30 minutes of market opening. Among the major laggards, $SUNPHARMA , $CIPLA and !Dr. Reddy’s Laboratories emerged as top Nifty losers, while $GLAND tumbled over 5%, leading the sectoral decline. The proposed tariff structure includes duties rising to 100% from August 2028 and potentially 200% thereafter, raising concerns over export competitiveness and future earnings visibility for Indian pharmaceutical companies. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

#FundamentalViews#TrendingSectors

475 likes·22 comments